

(19) World Intellectual Property
Organization
International Bureau



15 DEC 2004



(43) International Publication Date
31 December 2003 (31.12.2003)

PCT

(10) International Publication Number
WO 2004/000358 A1

(51) International Patent Classification⁷: **A61K 47/00**

(21) International Application Number:
PCT/IL2003/000513

(22) International Filing Date: 16 June 2003 (16.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
150334 20 June 2002 (20.06.2002) IL

(71) Applicant and

(72) Inventor: SINTOV, Amnon [IL/IL]; 27 Oren Street, Omer
84965 (IL).

(72) Inventor; and

(75) Inventor/Applicant (for US only): GORODISCHER,
Raphael [IL/IL]; Harduf Street 21, 84965 Omer (IL).

(74) Agent: WOLFF, Bregman and Goller; P.O. Box 1352,
Jerusalem 91013 (IL).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- with amended claims

Date of publication of the amended claims: 25 March 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TRANSDERMAL DRUG DELIVERY SYSTEM

(57) Abstract: The invention provides a transdermal delivery system for local anesthetic, immunosuppressive and neurologically effective drugs, as well as for polypeptides and protein-based drugs, comprising a local anesthetic, immunosuppressive or neurologically effective drug, as well as a polypeptide or protein-based drug in combination with water-miscible tetraglycol and water for dissolving the drug in hydrogel form.



WO 2004/000358 A1

AMENDED CLAIMS

[Received by the International Bureau on 16 December 2003 (16.12.03)]
original claim 1 amended; original claim 8 deleted, new claim 13 added]

1. A transdermal delivery system for local anesthetic, immunosuppressive and neurologically effective drugs, as well as for polypeptides and protein-based drugs, comprising a local anesthetic, immunosuppressive or neurologically effective drug, as well as a polypeptide or protein-based drug in combination with water-miscible tetraglycol and water for dissolving said drug in hydrogel form, wherein said transdermal delivery system is in the form of a microemulsion.
2. A transdermal delivery system according to claim 1, further comprising an ionized polymer.
3. A transdermal delivery system according to claim 2, wherein said ionized polymer is selected from the group consisting of cationized guar gum, cellulose derivatives, acrylic polymers, polysaccharides, lipids, proteins and polyhydroxy compounds.
4. A transdermal delivery system according to claim 2, wherein said ionized polymer is a guar-based polymer, which serves as a gelling agent for said composition.
5. A transdermal delivery system according to claim 3, wherein said guar-based polymer is hydroxypropyl guar hydroxypropyltrimonium chloride.
6. A transdermal delivery system according to claim 1, wherein said drug is selected from the group consisting of granisetron, lidocaine, and cyclosporine.
7. A transdermal delivery system according to claim 1, wherein said transdermal delivery system is in the form of a hydrogel patch.
9. A transdermal delivery system according to claim 1, further comprising a skin penetration enhancer.
10. A transdermal delivery system according to claim 9, wherein said skin penetration enhancer is a non-ionic surfactant.
11. A transdermal delivery system according to claim 10, wherein said non-ionic surfactant is selected from the group consisting of sorbitan sesquioleate, cetostearyl alcohol, polysorbate 60, sorbitan monostearate, sorbitan

monooleate, polyoxyethylene 23 lauryl alcohol, glyceryl mono/di-oleate and mixtures thereof.

12. A transdermal delivery system for an alcohol-miscible drug comprising an alcohol-miscible drug in combination with water-miscible tetraglycol and water for dissolving said drug in hydrogel form.
13. A topical delivery system for local anesthetic, immunosuppressive and neurologically effective drugs, as well as for polypeptides and protein-based drugs, comprising a local anesthetic, immunosuppressive or neurologically effective drug, as well as a polypeptide or protein-based drug in combination with water-miscible tetraglycol and water for dissolving said drug in hydrogel form, wherein said topical delivery system is in the form of a microemulsion.